{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:19:36Z","timestamp":1790720376576,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1097\/rlu.0000000000001629","type":"journal-article","created":{"date-parts":[[2017,3,4]],"date-time":"2017-03-04T14:03:54Z","timestamp":1488636234000},"page":"436-443","source":"Crossref","is-referenced-by-count":73,"title":["Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors"],"prefix":"10.1097","volume":"42","author":[{"given":"Mohammadali","family":"Hamiditabar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzammil","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Roys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Wolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"O'Dorisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Tworowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.","family":"Strosberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebrahim S.","family":"Delpassand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210204","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1067\/j.cpsurg.2006.03.002","article-title":"Carcinoid tumors","volume":"43","author":"Raut","year":"2006","journal-title":"Curr Probl Surg"},{"key":"R2-4-20210204","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"R3-4-20210204","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11912-009-0028-0","article-title":"Progress in the treatment of neuroendocrine tumors","volume":"11","author":"Chan","year":"2009","journal-title":"Curr Oncol Rep"},{"key":"R4-4-20210204","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000080731","article-title":"Epidemiology of neuroendocrine tumours","volume":"80","author":"Taal","year":"2004","journal-title":"Neuroendocrinology"},{"key":"R5-4-20210204","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","article-title":"Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin","volume":"81","author":"Mitry","year":"1999","journal-title":"Br J Cancer"},{"key":"R6-4-20210204","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00259-011-1835-8","article-title":"Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)","volume":"38","author":"Sowa-Staszczak","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R7-4-20210204","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","article-title":"Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue","volume":"315","author":"Kvols","year":"1986","journal-title":"N Engl J Med"},{"key":"R8-4-20210204","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"R9-4-20210204","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1749-6632.1994.tb17300.x","article-title":"Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history","volume":"733","author":"Krenning","year":"1994","journal-title":"Ann N Y Acad Sci"},{"key":"R10-4-20210204","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Bodei","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R11-4-20210204","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/MPA.0000000000000113","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience","volume":"43","author":"Delpassand","year":"2014","journal-title":"Pancreas"},{"key":"R12-4-20210204","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"R13-4-20210204","first-page":"1660","article-title":"Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy","volume":"45","author":"Nguyen","year":"2004","journal-title":"J Nucl Med"},{"key":"R14-4-20210204","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1097\/MNM.0000000000000547","article-title":"Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics","volume":"37","author":"Thapa","year":"2016","journal-title":"Nucl Med Commun"},{"key":"R15-4-20210204","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s002590100574","article-title":"[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients","volume":"28","author":"Kwekkeboom","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"R16-4-20210204","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1007\/s00259-011-2039-y","article-title":"Lutetium-labelled peptides for therapy of neuroendocrine tumours","volume":"39","author":"Kam","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R17-4-20210204","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00259-003-1117-1","article-title":"86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)\u2013a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion","volume":"30","author":"Jamar","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R18-4-20210204","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.2004.10.016","article-title":"Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate","volume":"22","author":"Teunissen","year":"2004","journal-title":"J Clin Oncol"},{"key":"R19-4-20210204","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1677\/ERC-09-0078","article-title":"Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors","volume":"17","author":"Kwekkeboom","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"R20-4-20210204","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00259-010-1631-x","article-title":"Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours","volume":"38","author":"Claringbold","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R21-4-20210204","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2967\/jnumed.111.087932","article-title":"Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate","volume":"52","author":"Khan","year":"2011","journal-title":"J Nucl Med"},{"key":"R22-4-20210204","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000335018","article-title":"Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy","volume":"97","author":"van Vliet","year":"2013","journal-title":"Neuroendocrinology"},{"key":"R23-4-20210204","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s002590050462","article-title":"Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC","volume":"26","author":"Cremonesi","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"R24-4-20210204","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.beem.2007.01.007","article-title":"Neuroendocrine tumors. Peptide receptor radionuclide therapy","volume":"21","author":"Forrer","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R25-4-20210204","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","article-title":"Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors","volume":"23","author":"Kwekkeboom","year":"2005","journal-title":"J Clin Oncol"},{"key":"R26-4-20210204","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2967\/jnumed.113.125336","article-title":"Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate","volume":"55","author":"Ezziddin","year":"2014","journal-title":"J Nucl Med"},{"key":"R27-4-20210204","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.2967\/jnumed.112.117408","article-title":"Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotate","volume":"54","author":"van Vliet","year":"2013","journal-title":"J Nucl Med"},{"key":"R28-4-20210204","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/1097-0142(19940301)73:5<1505::AID-CNCR2820730530>3.0.CO;2-V","article-title":"Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study","volume":"73","author":"Bukowski","year":"1994","journal-title":"Cancer"},{"key":"R29-4-20210204","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","article-title":"Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"R30-4-20210204","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000001629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T06:18:33Z","timestamp":1620973113000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201706000-00004"}},"subtitle":["Six Years' Assessment"],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000001629","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}